Instituto de Saúde Pública - Universidade do Porto, Porto, Portugal.
Member of the European Laboratory Initiative on TB, HIV and Viral Hepatitis (ELI) core group. The additional members of the ELI core group are listed under Acknowledgements.
Euro Surveill. 2022 Jul;27(29). doi: 10.2807/1560-7917.ES.2022.27.29.2100930.
Technical advances in diagnostic techniques have permitted the possibility of multi-disease-based approaches for diagnosis and treatment monitoring of several infectious diseases, including tuberculosis (TB), human immunodeficiency virus (HIV), viral hepatitis and sexually transmitted infections (STI). However, in many countries, diagnosis and monitoring, as well as disease response programs, still operate as vertical systems, potentially causing delay in diagnosis and burden to patients and preventing the optimal use of available resources. With countries facing both human and financial resource constraints, during the COVID-19 pandemic even more than before, it is important that available resources are used as efficiently as possible, potential synergies are leveraged to maximise benefit for patients, continued provision of essential health services is ensured. For the infectious diseases, TB, HIV, hepatitis C (HCV) and STI, sharing devices and integrated services starting with rapid, quality-assured, and complete diagnostic services is beneficial for the continued development of adequate, efficient and effective treatment strategies. Here we explore the current and future potential (as well as some concerns), importance, implications and necessary implementation steps for the use of platforms for multi-disease testing for TB, HIV, HCV, STI and potentially other infectious diseases, including emerging pathogens, using the example of the COVID-19 pandemic.
诊断技术的进步使得基于多种疾病的方法有可能用于诊断和监测几种传染病，包括结核病（TB）、人类免疫缺陷病毒（HIV）、病毒性肝炎和性传播感染（STI）。然而，在许多国家，诊断和监测以及疾病应对计划仍然作为垂直系统运作，这可能导致诊断延误和患者负担增加，并阻碍对现有资源的最佳利用。由于各国都面临人力和财力资源的限制，在 COVID-19 大流行期间，甚至比以往任何时候都更加重要的是，尽可能有效地利用现有资源，利用潜在的协同作用使患者受益最大化，确保继续提供基本的卫生服务。对于传染病，结核病、HIV、丙型肝炎（HCV）和 STI，从快速、质量保证和完整的诊断服务开始共享设备和整合服务，有利于继续制定充足、高效和有效的治疗策略。在这里，我们探讨了在 COVID-19 大流行的背景下，使用多疾病检测平台的当前和未来潜力（以及一些关注点）、重要性、影响和必要的实施步骤，这些平台可用于 TB、HIV、HCV、STI 以及可能的其他传染病，包括新出现的病原体。
